MedPath

To evaluate the efficacy of Eranda taila Matrabasti with Tamsulosin tablet in the management of vatashtheela (mutraghata) w.s.r to benign prostatic hyperplasia.

Not yet recruiting
Conditions
Benign prostatic hyperplasia withlower urinary tract symptoms. Ayurveda Condition: VATASHTHILA,
Registration Number
CTRI/2025/05/086983
Lead Sponsor
Matoshri Asarabai Darade Ayurved College,Babhulgaon,Yeola
Brief Summary

Acharya Sushruta The father of indian surgery has described 12 types of Mutraghata in uttartantra and also described the management of mutraghata which includes Basti,Uttarbasti,Virechan etc. Chikitsa.

As ayurveda is an ancient science of medicine, had explained about the disease of urinary tract system i.e Mutraghata srotas under the topic of Mutrakricchara,Mutraghata, ashmari.

Acharya Charaka has explained, an Apan Vayu is situated in the space between rectum and urinary bladder which produced a hard swelling like a stone,which is mobile,elevated ,and glandular . Which obstruct the passage of urine and feaces and produce symptoms like sanga.

Prostate gland is the part of male reproductive system, it is of walnut size and weight about 1 ounce i.e 24 grams.Prostate is present below the urinary bladder and infront of rectum. it goes around the tube called urethra which carries urine from bladder out through penis.

BPH is enlargement of medial lobe of prostate is responsible for obstruction of urethra. This lobe upwards into the bladder.

Medicines like ALPHA BLOCKERS i.e Tamsulosin is effective in benign prostatic hyperplasia. Tamsulosin works by relaxing the muscle around the bladder and prostate gland so urine is passed more easily. This helps empty the bladder completely and reduces the need to pass urine frequently or urgently in BPH.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Male
Target Recruitment
64
Inclusion Criteria
  • 1.Age group between 40 yrs to 70 yrs.
  • 2.Classical sign and symptoms of Mutraghata (BPH).
  • 3.USG of prostate suggestive of increased size and weight.
  • 4.Significant post voidal urine of greater than 90CC upto 200 CC.
Exclusion Criteria
  • 1.Age below 40 yrs and above 70 yrs.
  • 2.Acute retention of urine.
  • 3.Severe urinary calculi with significant obstructive uropathy.
  • 5.Renal failure.
  • 6.Systemic diseases like HIV, Hepatitis, T2DM.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
6.Straining1st,14th,21st,28th
The patient will be diagnosed based on symptoms of Vatashteela (Mutraghata) explained in Ayurvdic and Modern texts.1st,14th,21st,28th
5.Weak Stream1st,14th,21st,28th
2.Frequency1st,14th,21st,28th
1.Incomplete Emptying1st,14th,21st,28th
3.Intermittency1st,14th,21st,28th
The parameters will be noted down before and after treatment.1st,14th,21st,28th
4.Urgency1st,14th,21st,28th
7.Nocturia1st,14th,21st,28th
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Matoshri Asarabai Darade Hospital,Babhulgaon,Yeola

🇮🇳

Nashik, MAHARASHTRA, India

Matoshri Asarabai Darade Hospital,Babhulgaon,Yeola
🇮🇳Nashik, MAHARASHTRA, India
Dr Kiran Uttam Sirsat
Principal investigator
07385349279
sirsat230@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.